Enveric Biosciences, Inc. $ENVB

What the company doesAI summary of filing

Enveric Biosciences is a preclinical-stage biotechnology company developing small-molecule neuroplastogenic therapeutics for psychiatric and neurological disorders. The company's lead candidate, EB-003, is a non-hallucinogenic derivative of DMT designed to selectively engage serotonin receptors and is currently in preclinical studies with the aim of advancing to first-in-human clinical trials. Enveric generates no revenue and makes money through licensing agreements, including out-licensing molecules from its Psybrary platform and in-licensing intellectual property; the company has out-licensed its EVM201 portfolio and holds patent rights to psychedelic-inspired compounds and cannabinoid conjugates. The company is advancing its pipeline through internal development and partnerships, with plans to submit investigational new drug applications to the FDA. [10-K 2026-03-27]

Segments: EVM301 Series (EB-003), EVM401 Series, Psybrary platform (psychedelic-inspired compounds), Cannabinoid conjugates and formulations